Truvitech’s patent-pending technology deploys machine learning and information theory in order to identify candidate drug targets. Having knowledge or one or more effective targets is critical for developing efficacious drugs, and also valuable for designing synergistic drug combinations. 


In addition to identifying drug targets, the platform can also identify biological components whose engagement must be avoided to maximize therapeutic efficacy (anti-targets). Together, these features provide an unprecedented advantage for drug discovery programs.